Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, single-dose, 3-arm parallel design comparative pharmacokinetic and safety Phase I study of BAT1706 versus EU-sourced Avastin (Registered Trademark) and US-sourced Avastin (Registered Trademark) administered in healthy subjects

Next Previous
X
Search
Trial Profile

Randomized, double-blind, single-dose, 3-arm parallel design comparative pharmacokinetic and safety Phase I study of BAT1706 versus EU-sourced Avastin (Registered Trademark) and US-sourced Avastin (Registered Trademark) administered in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Bio-Thera Solutions

    • Most Recent Events

    • 07 Dec 2023 According to a Bio-Thera Solutions media release, United States Food and Drug Administration has approved Avzivi (bevacizumab-tnjn), a biosimilar referencing Avastin.
    • 23 Apr 2019 Results published in the BioDrugs
    • 27 Jul 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top